Hormone replacement therapy for African American women: Missed opportunities for effective intervention

Menopause

Volumn 6, Issue 2, 1999, Pages 147-155

  Nicholson, Wanda K ^a   Brown, Arleen F ^b   Gathe, Julia ^c   Grumbach, Kevin ^d   Washington, A Eugene ^d,e   Pérez Stable, Eliseo J ^d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

African American; Coronary heart disease; Hormone replacement therapy; Observational studies

Indexed keywords

ARTICLE; CANCER RISK; CORONARY ARTERY DISEASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NEGRO; POSTMENOPAUSE OSTEOPOROSIS; RISK BENEFIT ANALYSIS;

AFRICAN AMERICANS; AGED; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DATA COLLECTION; FEMALE; GENITAL NEOPLASMS, FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; INTERVENTION STUDIES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; POLICY MAKING; POSTMENOPAUSE; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 0033058322     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
2. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
3. Hammond CB. Menopause and hormone replacement therapy: an overview. Obstet Gynecol 1996:2S-15S.
4. Lenfant C. Report of the NHLBI working group on research in coronary heart disease in blacks. Circulation 1994;90:1613-23.
5. Lindsay R. The menopause and osteoporosis. Obstet Gynecol 1996:165-195.
6. Cummings SR, Rubin SM, Black D. The future of hip fractures in the United States: numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop 1990:163-6.
7. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Race and sex differences in mortality following fracture of the hip. Am J Public Health 1992;82:1147-50.
8. Furstenberg AL, Mezey MD. Differences in outcome between black and white elderly hip fracture patients. J Chronic Dis 1987;40:931-8.
9. Silverman SL, Madison RE. Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California hospital discharge data. Am J Public Health 1988;78:1482-3.
10. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: study of osteoporotic fractures research group. N Engl J Med 1995;332:767-73.
11. Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for hip fracture in black women: the northeast hip fracture study group. N Engl J Med 1994;330:1555-9.
12. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178-208.
13. Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE. Survival experience of aged hip fracture patients. Am J Public Health 1989;79:274-8.
14. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
15. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987;317:1169-74.
16. Johnson RE, Specht EE. The risk of hip fracture in postmenopausal females with or without estrogen drug exposure. Am J Public Health 1981;71:138-44.
17. Paganini HA, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981;95:28-31.
18. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture: A prospective, population-based cohort study. Ann Intern Med 1990;113:95-103.
19. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
20. Paganini HA, Chao A, Ross RK, Henderson BE. Exercise and other factors in the prevention of hip fracture: the Leisure World study. Epidemiology 1991;2:16-25.
21. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
22. Williams AR, Weiss NS, Ure CL, Ballard J, Daling JR. Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gynecol 1982;60:695-9.
23. Kreiger N, Kelsey JL, Holford TR, O'Connor T. An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol 1982;116:141-8.
24. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol 1979;133:537-47.
25. Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius: a case-control study. Lancet 1979; 2(8145):705-9.
26. Liao Y, Cooper RS. Continued adverse trends in coronary heart disease mortality among blacks: 1980-91. Public Health Rep 1995;110:572-9; discussion 570-2.
27. Lee MH, Borhani NO, Kuller LH. Validation of reported myocardial infarction mortality in blacks and whites: a report from the community cardiovascular surveillance program. Ann Epidemiol 1990;1:1-12.
28. Maynard C, Fisher LD, Passamani ER, Pullum T. Blacks in the coronary artery surgery study (CASS): race and clinical decision making. Am J Public Health 1986;76:1445-8.
29. Rosenberg L, Armstrong B, Jick H. Letter: Myocardial infarction and estrogen therapy in premenopausal women. N Engl J Med 1976;294:1290-1.
30. Otten MJ, Teutsch SM, Williamson DF, Marks JS. The effect of known risk factors on the excess mortality of black adults in the United States . JAMA 1990;263:845-50.